Framework, Organization, and Applications of the Simcyp Population-Based Simulator to Support New Drug Development

[1]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[2]  Casopitant: In Vitro Data and SimCyp Simulation to Predict In Vivo Metabolic Interactions Involving Cytochrome P450 3A4 , 2011, Drug Metabolism and Disposition.

[3]  G. Tucker,et al.  Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. , 1986, British journal of clinical pharmacology.

[4]  A Rostami-Hodjegan,et al.  Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. , 2010, Current drug metabolism.

[5]  M. Mugford,et al.  Genetic health technology and economic evaluation , 2006, Applied health economics and health policy.

[6]  A J Atkinson,et al.  Systems Clinical Pharmacology , 2010, Clinical pharmacology and therapeutics.

[7]  S. Golder,et al.  Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment , 2012, PharmacoEconomics.

[8]  K. G. Jensen,et al.  Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  M. Jamei,et al.  Modeling and predicting drug pharmacokinetics in patients with renal impairment , 2011, Expert review of clinical pharmacology.

[10]  N. Waters,et al.  Integrated in Vitro Analysis for the in Vivo Prediction of Cytochrome P450-Mediated Drug-Drug Interactions , 2008, Drug Metabolism and Disposition.

[11]  L. Wienkers,et al.  Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation , 2010, Drug Metabolism and Disposition.

[12]  M. Monshouwer,et al.  Determination of Time-Dependent Inactivation of CYP3A4 in Cryopreserved Human Hepatocytes and Assessment of Human Drug-Drug Interactions , 2011, Drug Metabolism and Disposition.

[13]  Kazuya Maeda,et al.  Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.

[14]  S. Vegter,et al.  Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature , 2010 .

[15]  T. Arafat,et al.  Effect of Microgravity on the Pharmacokinetics of Ibuprofen in Humans , 2011, Journal of clinical pharmacology.

[16]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[17]  J R Powell,et al.  Pharmacometrics at FDA: Evolution and Impact on Decisions , 2007, Clinical pharmacology and therapeutics.

[18]  Granville Sewell,et al.  The numerical solution of ordinary and partial differential equations , 2005 .

[19]  B. Lum,et al.  The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition , 2007, European Journal of Clinical Pharmacology.

[20]  A. Gelman,et al.  Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .

[21]  James E. Bennett,et al.  The Bayesian modeling of covariates for population pharmacokinetic models , 1996 .

[22]  A E Ades,et al.  Use of evidence in economic decision models: practical issues and methodological challenges. , 2007, Health economics.

[23]  J. Shin,et al.  Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin , 2008, Clinical pharmacology and therapeutics.

[24]  B. O'brien,et al.  Economic Considerations for Health Insurance Coverage of Emerging Genetic Tests , 2003, Public Health Genomics.

[25]  Yuan Chen,et al.  Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies , 2012, Biopharmaceutics & drug disposition.

[26]  Masoud Jamei,et al.  Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[27]  Katherine Payne,et al.  The Appropriate Elicitation of Expert Opinion in Economic Models , 2011, PharmacoEconomics.

[28]  M. H. Ensom,et al.  Pharmacogenetics , 2001, Clinical pharmacokinetics.

[29]  D. Cortese,et al.  Severe hypoxemia and liver disease. , 1989, The American review of respiratory disease.

[30]  M. Jamei,et al.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.

[31]  C. Flowers,et al.  The Role of Cost-Effectiveness Analysis in the Era of Pharmacogenomics , 2012, PharmacoEconomics.

[32]  Robert J Riley,et al.  Time-dependent CYP inhibition , 2007, Expert opinion on drug metabolism & toxicology.

[33]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[34]  W. Newman,et al.  Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom , 2010, British Journal of Cancer.

[35]  Saeed Rezaee,et al.  Incorporating In Vitro Information on Drug Metabolism Into Clinical Trial Simulations to Assess the Effect of CYP2D6 Polymorphism on Pharmacokinetics and Pharmacodynamics: Dextromethorphan as a Model Application , 2007, Journal of clinical pharmacology.

[36]  John C Lipscomb,et al.  Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.

[37]  I Zineh,et al.  Clinical Pharmacology and the Catalysis of Regulatory Science: Opportunities for the Advancement of Drug Development and Evaluation , 2013, Clinical pharmacology and therapeutics.

[38]  L. Wienkers,et al.  Predicting in vivo drug interactions from in vitro drug discovery data , 2005, Nature Reviews Drug Discovery.

[39]  C. Mathias.  Effect of food intake on cardiovascular control in patients with impaired autonomic function , 1990, Journal of Neuroscience Methods.

[40]  Lewis B. Sheiner,et al.  The NONMEM System , 1980 .

[41]  Amin Rostami-Hodjegan,et al.  Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. , 2009, British journal of clinical pharmacology.

[42]  L. Berezhkovskiy,et al.  Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. , 2004, Journal of pharmaceutical sciences.

[43]  Maarten J. Postma,et al.  Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes , 2012, PharmacoEconomics.

[44]  Katrina Armstrong,et al.  Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[45]  Elizabeth Foot,et al.  Pharmacogenetics--pivotal to the future of the biopharmaceutical industry. , 2010, Drug discovery today.

[46]  Anthony O'Hagan,et al.  Review of Statistical Methods for Analysing Healthcare Resources and Costs , 2010, Health economics.

[47]  C. Wolf,et al.  Science, medicine, and the future: Pharmacogenetics. , 2000, BMJ.

[48]  Alex Phipps,et al.  Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. , 2008, British journal of clinical pharmacology.

[49]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[50]  T. Nolin,et al.  Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport , 2008, Clinical pharmacology and therapeutics.

[51]  M. Wilson,et al.  Regulation of intestinal blood flow. , 2000, The Journal of surgical research.

[52]  F Kesisoglou,et al.  Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[53]  Kathryn A Phillips,et al.  A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. , 2004, Pharmacogenomics.

[54]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[55]  K Rowland-Yeo,et al.  Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[56]  Maurice Dickins,et al.  Maraviroc: in vitro assessment of drug-drug interaction potential. , 2008, British journal of clinical pharmacology.

[57]  Thomas R Fleming.  Objective response rate as a surrogate end point: a commentary. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  D. Rock,et al.  Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements , 2008 .

[59]  S. Duffy,et al.  Are adverse effects incorporated in economic models? An initial review of current practice. , 2009, Health technology assessment.

[60]  Anthony J Culyer,et al.  National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.

[61]  G. Tucker,et al.  Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[62]  Karl Claxton,et al.  Exploring Uncertainty in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.

[63]  L B Sheiner,et al.  Estimating population kinetics. , 1982, Critical reviews in biomedical engineering.

[64]  C. Oo,et al.  The Need for Multiple Doses of 400 mg Ketoconazole as a Precipitant Inhibitor of a CYP3A Substrate in an In Vivo Drug‐Drug Interaction Study , 2009, Journal of clinical pharmacology.

[65]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[66]  J. Lipscomb,et al.  Covariation of Human Microsomal Protein Per Gram of Liver with Age: Absence of Influence of Operator and Sample Storage May Justify Interlaboratory Data Pooling , 2008, Drug Metabolism and Disposition.

[67]  I. Bruce,et al.  Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription , 2007, Journal of clinical pharmacy and therapeutics.

[68]  G. Tucker,et al.  Measurement of the renal clearance of drugs. , 1981, British journal of clinical pharmacology.

[69]  G Levy,et al.  Effect of plasma protein binding on renal clearance of drugs. , 1980, Journal of pharmaceutical sciences.

[70]  M. Jamei,et al.  Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients , 2011, Clinical pharmacokinetics.

[71]  U. Klotz,et al.  The effects of age and liver disease on the disposition and elimination of diazepam in adult man. , 1975, The Journal of clinical investigation.

[72]  G. Skiles,et al.  Simulation of Clinical Drug-Drug Interactions from Hepatocyte CYP3A4 Induction Data and Its Potential Utility in Trial Designs , 2011, Drug Metabolism and Disposition.

[73]  Marie Davidian,et al.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[74]  A. Beresford,et al.  The emerging importance of predictive ADME simulation in drug discovery. , 2002, Drug discovery today.

[75]  F. Trevisani,et al.  The hemodynamic status of preascitic cirrhosis: An evaluation under steady‐state conditions and after postural change , 1992, Hepatology.

[76]  Sebastian Polak,et al.  Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.

[77]  B. Scribner,et al.  Non-ionic diffusion and the excretion of weak acids and bases. , 1958, The American journal of medicine.

[78]  M C Weinstein,et al.  Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. , 2001, International journal of technology assessment in health care.

[79]  Amin Rostami-Hodjegan,et al.  Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug–drug interactions: using in vitro data as an aid to assess study power , 2009, Pharmaceutical statistics.

[80]  I. Janků.  Physiological modelling of renal drug clearance , 2006, European Journal of Clinical Pharmacology.

[81]  Eberechukwu Onukwugha,et al.  Sensitivity Analysis in Cost-Effectiveness Studies , 2011, PharmacoEconomics.

[82]  Goonaseelan Pillai,et al.  Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[83]  Kathryn A. Phillips,et al.  Measuring the value of pharmacogenomics , 2005, Nature Reviews Drug Discovery.

[84]  Karl Claxton,et al.  Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence? , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[85]  M. Sculpher,et al.  Catalogue of EQ-5D Scores for the United Kingdom , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[86]  Sarah Wordsworth,et al.  Eliciting expert opinion for economic models: an applied example. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[87]  Daniel Röshammar,et al.  In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. , 2011, British journal of clinical pharmacology.

[88]  E. Burchard,et al.  Effects of Genetic Variation in the Novel Organic Cation Transporter, OCTN1, on the Renal Clearance of Gabapentin , 2008, Clinical pharmacology and therapeutics.

[89]  G T Tucker,et al.  Pharmacokinetic-pharmacogenetic modelling in the detection of polymorphisms in xenobiotic metabolism. , 1990, The Annals of occupational hygiene.

[90]  Katherine Payne,et al.  A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. , 2011, Pharmacogenomics.

[91]  M. Bala,et al.  Overview of the pharmacoeconomics of pharmacogenetics. , 2006, Pharmacogenomics.

[92]  I. Tomlinson,et al.  Molecular testing for somatic cancer mutations: a survey of current and future testing in UK laboratories , 2007, Journal of Clinical Pathology.

[93]  G. Tucker,et al.  Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies--moving the "goalposts" or changing the "game". , 1994, Journal of pharmaceutical sciences.

[94]  Josh J. Carlson,et al.  Cost Effectiveness of Pharmacogenomics , 2012, PharmacoEconomics.

[95]  Robert J Riley,et al.  Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[96]  Brian Tomlinson,et al.  OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine , 2008, Pharmacogenetics and genomics.

[97]  F Y Bois,et al.  An analysis of exposure rate effects for benzene using a physiologically based pharmacokinetic model. , 1992, Regulatory toxicology and pharmacology : RTP.

[98]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[99]  Kairui Feng,et al.  The Simcyp® Population-based ADME Simulator , 2009 .

[100]  M. Jamei,et al.  PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. , 2010, Toxicology.

[101]  B. O'brien,et al.  The death of cost-minimization analysis? , 2001, Health economics.

[102]  Melvin E. Andersen,et al.  What do we Mean by Dose , 1995 .

[103]  G. Tucker,et al.  Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[104]  Katherine Payne,et al.  Fish and chips all round? Regulation of DNA-based genetic diagnostics. , 2009, Health economics.

[105]  T. Lavé,et al.  A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics , 2006, Clinical pharmacokinetics.

[106]  M. Jamei,et al.  Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[107]  K Rowland-Yeo,et al.  Prediction of metabolic drug clearance in humans: In vitro–in vivo extrapolation vs allometric scaling , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[108]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[109]  S. Ramsey,et al.  Economic analyses of human genetics services: A systematic review , 2005, Genetics in Medicine.

[110]  Richard D. Smith,et al.  Contingent valuation: (still) on the road to nowhere? , 2009, Health economics.

[111]  Amin Rostami-Hodjegan,et al.  Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children , 2006, Clinical pharmacokinetics.

[112]  G. Tucker,et al.  A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance , 2010, Clinical pharmacokinetics.

[113]  Amin Rostami-Hodjegan,et al.  Changes in liver volume from birth to adulthood: A meta‐analysis , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[114]  Kenneth B Wells,et al.  Burden of Illness , 1968 .

[115]  C. Masimirembwa,et al.  In Vitro and in Silico Identification and Characterization of Thiabendazole as a Mechanism-Based Inhibitor of CYP1A2 and Simulation of Possible Pharmacokinetic Drug-Drug Interactions , 2009, Drug Metabolism and Disposition.

[116]  Maurice Dickins,et al.  Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man , 2008 .

[117]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.

[118]  R. Obach,et al.  Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism‐based adverse events , 2012, Biopharmaceutics & drug disposition.

[119]  A. Rostami-Hodjegan,et al.  Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter‐system extrapolation factors , 2011, Biopharmaceutics & drug disposition.

[120]  M. Drummond,et al.  The Iterative Use of Economic Evaluation as Part of the Process of Health Technology Assessment , 1997, Journal of health services research & policy.

[121]  Malcolm Rowland,et al.  Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes , 2007, Pharmaceutical Research.

[122]  G. Tucker,et al.  Backtracking booze with Bayes--the retrospective interpretation of blood alcohol data. , 1991, British journal of clinical pharmacology.

[123]  Amin Rostami-Hodjegan,et al.  The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. , 2007, British journal of clinical pharmacology.